Foncinvez product

Consider FOCINVEZ™

The first and only ready-to-use presentation of fosaprepitant — without the need for dilution or reconstitution1,2

About FOCINVEZ™
Learn more
Product
Information
Learn more
Support
Learn more
Resources
GET RESOURCES

FOCINVEZ™ is supplied in the dose strength of 150 mg/50 mL (3 mg/mL).1 Please see Full Prescribing Information for a complete list of indications and dosing schedule.


References: 1. FOCINVEZ. Prescribing information. Amneal Pharmaceuticals LLC; 2026. 2. U.S. Food and Drug Administration. Orange book: Approved drug products with therapeutic equivalence evaluations. Accessed September 15, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm

Learn more about FOCINVEZ™

Go

FOCINVEZ™ IMPORTANT SAFETY INFORMATION

FOCINVEZ™ is a substance P/neurokinin-1(NK1) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:

  • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
  • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use:

FOCINVEZ™ has not been studied for treatment of established nausea and vomiting.

CONTRAINDICATIONS

  • Patients who are hypersensitive to any component of the product: Hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported.
  • Patients who are taking pimozide: Inhibition of CYP3A4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide.

WARNINGS AND PRECAUTIONS

Clinically Significant CYP3A4 Drug Interactions: Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4.

  • Use of FOCINVEZ™ with other drugs that are CYP3A4 substrates, may result in increased plasma concentration of the concomitant drug. Use of pimozide with FOCINVEZ™ is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide.
  • Use of FOCINVEZ™ with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to FOCINVEZ™.
  • Use of FOCINVEZ™ with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of FOCINVEZ™.

Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, during or soon after infusion of fosaprepitant have occurred. Symptoms including flushing, erythema, dyspnea, hypotension and syncope have been reported. Patients should be monitored during and after infusion. If hypersensitivity reactions occur, discontinue the infusion and administer appropriate medical therapy. Do not reinitiate FOCINVEZ™ in patients who experience these symptoms with previous use.

Infusion Site Reactions: Infusion site reactions (ISRs) have been reported with the use of intravenous fosaprepitant. The majority of severe ISRs, including thrombophlebitis and vasculitis, were reported with concomitant vesicant (anthracycline-based) chemotherapy administration, particularly when associated with extravasation. Necrosis was also reported in some patients with concomitant vesicant chemotherapy. Most ISRs occurred with the first, second or third exposure to single doses of intravenous fosaprepitant and in some cases, reactions persisted for two weeks or longer. Treatment of severe ISRs consisted of medical, and in some cases surgical, intervention. Avoid infusion of FOCINVEZ™ into small veins or through a butterfly catheter. If a severe ISR develops during infusion, discontinue the infusion and administer appropriate medical treatment.

Decrease INR with Concomitant Warfarin: Co-administration of fosaprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of FOCINVEZ™ with each chemotherapy cycle.

Risk of Reduced Efficacy of Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of fosaprepitant. Advise patients to use effective alternative or back-up methods of contraception during treatment with FOCINVEZ™ and for 1 month following administration of the last dose of fosaprepitant or oral aprepitant.

ADVERSE REACTIONS

  • The most common adverse reactions in adults (> 2%) for the prevention of nausea and vomiting associated with MEC include fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, and pain in extremity.
  • The most common adverse reactions in adults receiving HEC were generally similar to those observed in the MEC study, except for infusion-site reactions, which occurred more often with fosaprepitant (3.0%) than with aprepitant.
  • Adverse reactions in pediatric patients are similar to those observed in adults.

Side effects other than those listed above are possible with the use of FOCINVEZ™.

See the full Prescribing Information for a list of all possible side effects.

DRUG INTERACTIONS:

  • When administered intravenously, fosaprepitant, a prodrug of aprepitant, is converted to aprepitant within 30 minutes. Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, inducer of CYP3A4, and an inducer of CYP2C9.
  • Some substrates of CYP3A4 (pimozide) are contraindicated with FOCINVEZ™. Dosage adjustment of other CYP3A4 and CYP2C9 substrates may be warranted.
  • See full Prescribing Information for a list of clinically significant drug interactions and management instructions for interacting medications.

USE IN SPECIFIC POPULATIONS

  • Pregnancy: There are insufficient data on use of fosaprepitant in pregnant women to identify a drug associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
  • Lactation: There are no data on the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for FOCINVEZ™ and any potential adverse effects on the breastfed infant from FOCINVEZ™ or from the underlying maternal condition.
  • Females and Males of Reproductive Potential: Upon administration of FOCINVEZ™, the efficacy of hormonal contraceptives may be reduced. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraceptive (such as condoms and spermicides) during treatment with FOCINVEZ™ and for 1 month following the last dose of fosaprepitant or oral aprepitant.
  • Pediatric Use: The safety and effectiveness of FOCINVEZ™ for the prevention of nausea and vomiting associated with HEC or MEC have not been established in patients less than 6 months of age.
  • Geriatric Use: No clinically meaningful differences in the pharmacokinetics of oral aprepitant were observed in healthy adult subjects 65 years of age and over compared to younger adult subjects.
  • Patients With Hepatic Impairment: There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score greater than 9). Therefore, additional monitoring for adverse reactions in these patients may be warranted when FOCINVEZ™ is administered to patients with severe hepatic impairment.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Global Patient Safety at 1-877-835-5472, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information.

PP-FOC-US-0003 10/2026

INDICATIONS

FOCINVEZ™ is a substance P/neurokinin-1(NK1) receptor antagonist, indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:

+